Clinical trials
Allogeneic Hematopoietic Stem Cell Transplantation clinical trials
Below are recruiting allogeneic hematopoietic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 262 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06575296RecruitingPhase 1
Revumenib after stem cell transplant for acute leukemia
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
Duarte, CaliforniaAges 2 years+ - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT06633328RecruitingEarly Phase 1
Cd7 car-t before stem cell transplant for severe aplastic anemia
This trial tests a new approach: first, you receive a specially engineered immune cell treatment (CD7 CAR-T) to help prepare your body, then a stem cell transplant from a relative. It's designed for people with severe aplastic anemia who cannot have or choose not to get a standard transplant.
Hanzhou, ZhejiangAges Any age - NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT06676852Recruiting
Palliative care support for stem cell transplant patients
This study tests whether adding a palliative care program (extra support for comfort and quality of life) is helpful for people receiving a stem cell transplant. It aims to see if patients and doctors find it useful and easy to use.
Boston, MassachusettsAges 18 years+ - NCT06681922RecruitingPhase 1/Phase 2
A new combination to prevent graft-versus-host disease after stem cell transplant
This study tests a combination of three drugs—high-dose cyclophosphamide, bortezomib, and abatacept—after a donor stem cell transplant to see if they can better prevent graft-versus-host disease (a condition where donor cells attack the body).
Lake Success, New YorkAges 18 years+ - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT06704152RecruitingPhase 1/Phase 2
A cell therapy for blood cancers after stem cell transplant
This trial tests a new cell therapy (BSB-1001) given after a stem cell transplant to prevent or treat high-risk blood cancers like AML, ALL, or MDS. It is for patients with a specific genetic marker and a matched donor.
Duarte, CaliforniaAges 18–70 - NCT06705062RecruitingPhase 3
Reduced vs standard GVHD prevention in stem cell transplant
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Atlanta, GeorgiaAges 18–75 - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT07548983RecruitingPhase 1
Ruxolitinib and azacitidine after stem cell transplant for acute myeloid leukemia
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
Portland, OregonAges 18 years+ - NCT01666080Recruiting
Second bone marrow transplant with gentler chemotherapy
This trial studies a “reduced intensity” second transplant using donated blood-forming cells, for people whose first transplant did not fully and reliably restart blood production. It aims to improve donor blood cell growth while using a less harsh conditioning approach.
Minneapolis, MinnesotaAges Up to 55 years - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06715046Recruiting
Blood DNA test after stem cell transplant
This study checks if looking at DNA in your blood can help doctors see how well your stem cell transplant is working and catch any problems early. It is for people with blood cancers getting a transplant from a donor.
Milan, MilanAges 18 years+ - NCT06735690RecruitingEarly Phase 1
Immune cells plus vaccine after stem cell transplant for leukemia
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Duarte, CaliforniaAges 18 years+ - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT06809712RecruitingPhase 1
Stem cell transplant from a partially matched unrelated donor
This trial tests a transplant using stem cells from an unrelated donor who is not a perfect match for your tissue type. It may be an option for people with blood cancers who can't find a fully matched related donor and need a transplant quickly.
HangzhouAges 18–60 - NCT06809699RecruitingPhase 1
Stem cell transplant using a partially matched family donor
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hangzhou, ChinaAges 18–60 - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT06845592Recruiting
Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Perugia, PGAges 18–65
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic hematopoietic stem cell transplantation?
- Yes. Clin2 currently lists 262 recruiting allogeneic hematopoietic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic hematopoietic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic hematopoietic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.